These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21156282)

  • 1. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.
    Calado DP; Zhang B; Srinivasan L; Sasaki Y; Seagal J; Unitt C; Rodig S; Kutok J; Tarakhovsky A; Schmidt-Supprian M; Rajewsky K
    Cancer Cell; 2010 Dec; 18(6):580-9. PubMed ID: 21156282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.
    Mandelbaum J; Bhagat G; Tang H; Mo T; Brahmachary M; Shen Q; Chadburn A; Rajewsky K; Tarakhovsky A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2010 Dec; 18(6):568-79. PubMed ID: 21156281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.
    Compagno M; Lim WK; Grunn A; Nandula SV; Brahmachary M; Shen Q; Bertoni F; Ponzoni M; Scandurra M; Califano A; Bhagat G; Chadburn A; Dalla-Favera R; Pasqualucci L
    Nature; 2009 Jun; 459(7247):717-21. PubMed ID: 19412164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
    Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
    Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
    Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
    Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL.
    Nogai H; Wenzel SS; Hailfinger S; Grau M; Kaergel E; Seitz V; Wollert-Wulf B; Pfeifer M; Wolf A; Frick M; Dietze K; Madle H; Tzankov A; Hummel M; Dörken B; Scheidereit C; Janz M; Lenz P; Thome M; Lenz G
    Blood; 2013 Sep; 122(13):2242-50. PubMed ID: 23869088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
    Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
    Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.
    Habineza Ndikuyeze G; Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Flood P; Krick E; Propert KJ; Mason NJ
    PLoS One; 2014; 9(5):e95404. PubMed ID: 24798348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
    Pasqualucci L; Compagno M; Houldsworth J; Monti S; Grunn A; Nandula SV; Aster JC; Murty VV; Shipp MA; Dalla-Favera R
    J Exp Med; 2006 Feb; 203(2):311-7. PubMed ID: 16492805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
    Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
    J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
    Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
    J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.